Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–60. https://doi.org/10.1016/j.annonc.2020.03.304.

Article  CAS  PubMed  Google Scholar 

Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, et al. Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol. 2021;32:439–51. https://doi.org/10.1016/j.annonc.2021.01.003.

Article  CAS  PubMed  Google Scholar 

Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, Reed NS, et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35:e13249. https://doi.org/10.1111/jne.13249.

Article  CAS  PubMed  Google Scholar 

Kos-Kudła B, Castaño JP, Denecke T, Grande E, Kjaer A, Koumarianou A, et al. European neuroendocrine tumour society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35:e13343. https://doi.org/10.1111/jne.13343.

Article  CAS  PubMed  Google Scholar 

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united States. JAMA Oncol. 2017;3:1335–42. https://doi.org/10.1001/jamaoncol.2017.0589.

Article  PubMed  PubMed Central  Google Scholar 

Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an international agency for research on Cancer (IARC) and world health organization (WHO) expert consensus proposal. Mod Pathol. 2018;31:1770–86. https://doi.org/10.1038/s41379-018-0110-y.

Article  PubMed  PubMed Central  Google Scholar 

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33:115–54. https://doi.org/10.1007/s12022-022-09708-2.

Article  CAS  PubMed  Google Scholar 

Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, et al. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist. 2018;23:422−32. https://doi.org/10.1634/theoncologist.2017-0364

Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) Well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40:1192–202. https://doi.org/10.1097/pas.0000000000000662.

Article  PubMed  PubMed Central  Google Scholar 

Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, et al. International union of basic and clinical pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev. 2018;70:763–835. https://doi.org/10.1124/pr.117.015388.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ. Alternate endpoints for screening phase II studies. Clin Cancer Res. 2009;15:1873–82. https://doi.org/10.1158/1078-0432.Ccr-08-2034.

Article  CAS  PubMed  Google Scholar 

Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, et al. Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms. Endocr Relat Cancer. 2017;24:475–83. https://doi.org/10.1530/erc-17-0197.

Article  CAS  PubMed  Google Scholar 

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol. 2011;29:934–43. https://doi.org/10.1200/jco.2010.33.2056.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33. https://doi.org/10.1056/NEJMoa1316158.

Article  CAS  PubMed  Google Scholar 

Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, et al. Placebo-Controlled, Double-Blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol. 2009;27:4656–63. https://doi.org/10.1200/jco.2009.22.8510.

Article  CAS  PubMed  Google Scholar 

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23. https://doi.org/10.1056/NEJMoa1009290.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or Gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–77. https://doi.org/10.1016/S0140-6736(15)00817-X.

Article  CAS  PubMed  Google Scholar 

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13. https://doi.org/10.1056/NEJMoa1003825.

Article  CAS  PubMed  Google Scholar 

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high–dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024. https://doi.org/10.1016/s0140-6736(24)00701-3.

Article  PubMed  PubMed Central  Google Scholar 

Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs–twenty-first Richard and Hinda rosenthal foundation award lecture. Clin Cancer Res. 1998;4:1079–86.

Google Scholar 

Von Hoff DD, Stephenson JJ Jr., Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28:4877–83. https://doi.org/10.1200/jco.2009.26.5983.

Article  Google Scholar 

Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25:751–8. https://doi.org/10.1038/s41591-019-0424-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, et al. Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017;87:122–30. https://doi.org/10.1016/j.ejca.2017.10.013.

Article  PubMed  Google Scholar 

Prager GW, Unseld M, Waneck F, Mader R, Wrba F, Raderer M, et al. Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. Oncotarget. 2019;10:942–52. https://doi.org/10.18632/oncotarget.26604.

Article  PubMed  PubMed Central  Google Scholar 

van de Kruis N, van der Ploeg P, Wilting JHC, Caroline Vos M, Thijs AMJ, de Hullu J, et al. The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: current and future perspectives. Gynecol Oncol Rep. 2022;42:101035. https://doi.org/10.1016/j.gore.2022.101035.

Article  PubMed  PubMed Central  Google Scholar 

du Rusquec P, Guimbaud R, Le Malicot K, Gornet JM, Nguyen S, Lecomte T, et al. Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens. ESMO Open. 2023;8:101616. https://doi.org/10.1016/j.esmoop.2023.101616.

Article  PubMed  PubMed Central  Google Scholar 

Doleschal B, Taghizadeh H, Webersinke G, Piringer G, Schreil G, Decker J, et al. Real world evide